{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T15:37:51Z","timestamp":1792424271369,"version":"4.5.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1681\/asn.2013020185","type":"journal-article","created":{"date-parts":[[2013,9,12]],"date-time":"2013-09-12T21:33:59Z","timestamp":1379021639000},"page":"150-158","source":"Crossref","is-referenced-by-count":83,"title":["Long-Term Outcomes in Idiopathic Membranous Nephropathy Using a Restrictive Treatment Strategy"],"prefix":"10.1681","volume":"25","author":[{"given":"Jan A.J.G.","family":"van den Brand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter R.","family":"van Dijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia M.","family":"Hofstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack F.M.","family":"Wetzels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-18-20230410","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy.","volume":"361","author":"Beck","year":"2009","journal-title":"N Engl J Med"},{"key":"R2-18-20230410","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.2215\/CJN.04020411","article-title":"Low-molecular-weight proteins as prognostic markers in idiopathic membranous nephropathy.","volume":"6","author":"van den Brand","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"R3-18-20230410","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1053\/j.ajkd.2005.08.020","article-title":"Idiopathic membranous nephropathy: Outline and rationale of a treatment strategy.","volume":"46","author":"du Buf-Vereijken","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"R4-18-20230410","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1038\/ki.1995.453","article-title":"A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy.","volume":"48","author":"Ponticelli","year":"1995","journal-title":"Kidney Int"},{"key":"R5-18-20230410","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1681\/ASN.2007020166","article-title":"A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy.","volume":"18","author":"Jha","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"R6-18-20230410","first-page":"186","article-title":"KDIGO clinical practice guideline for glomerulonephritis.","volume":"2","author":"KDIGO Working Group","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"R7-18-20230410","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/ndt\/gfr371","article-title":"Management of patients with membranous nephropathy.","volume":"27","author":"Hofstra","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"R8-18-20230410","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1093\/ndt\/gfq841","article-title":"Outcome of idiopathic membranous nephropathy using targeted stepwise immunosuppressive treatment strategy.","volume":"26","author":"Aaltonen","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"R9-18-20230410","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.2215\/CJN.11001210","article-title":"Have we changed the outcome in membranous nephropathy? A propensity study on the role of immunosuppressive therapy.","volume":"6","author":"Cattran","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"R10-18-20230410","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/qjmed\/hch059","article-title":"Restrictive use of immunosuppressive treatment in patients with idiopathic membranous nephropathy: high renal survival in a large patient cohort.","volume":"97","author":"du Buf-Vereijken","year":"2004","journal-title":"QJM"},{"key":"R11-18-20230410","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/ndt\/gfp390","article-title":"Early versus late start of immunosuppressive therapy in idiopathic membranous nephropathy: A randomized controlled trial.","volume":"25","author":"Hofstra","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"R13-18-20230410","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/j.1523-1755.2004.00873.x","article-title":"Idiopathic membranous nephropathy: Definition and relevance of a partial remission.","volume":"66","author":"Troyanov","year":"2004","journal-title":"Kidney Int"},{"key":"R14-18-20230410","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1681\/ASN.2009080861","article-title":"Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy.","volume":"21","author":"Polanco","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"R15-18-20230410","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S0140-6736(12)61566-9","article-title":"Immunosuppression for progressive membranous nephropathy: A UK randomised controlled trial.","volume":"381","author":"Howman","year":"2013","journal-title":"Lancet"},{"key":"R16-18-20230410","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1681\/ASN.V93444","article-title":"A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy.","volume":"9","author":"Ponticelli","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"R17-18-20230410","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/qjmed\/91.5.359","article-title":"Oral cyclophosphamide versus chlorambucil in the treatment of patients with membranous nephropathy and renal insufficiency.","volume":"91","author":"Branten","year":"1998","journal-title":"QJM"},{"key":"R18-18-20230410","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/MD.0b013e3181e93d00","article-title":"Efficacy and adverse events of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: systematic review and meta-analysis.","volume":"89","author":"Kamanamool","year":"2010","journal-title":"Medicine (Baltimore"},{"key":"R19-18-20230410","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2215\/CJN.04250511","article-title":"Venous thromboembolism in patients with membranous nephropathy.","volume":"7","author":"Lionaki","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"R20-18-20230410","doi-asserted-by":"crossref","first-page":"725","DOI":"10.7326\/0003-4819-114-9-725","article-title":"Sustained remission of membranous glomerulonephritis after cyclophosphamide and prednisone.","volume":"114","author":"Bruns","year":"1991","journal-title":"Ann Intern Med"},{"key":"R21-18-20230410","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1136\/ard.2003.019125","article-title":"Urinary bladder cancer in Wegener\u2019s granulomatosis: Risks and relation to cyclophosphamide.","volume":"63","author":"Knight","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"R22-18-20230410","first-page":"100","article-title":"Malignancies in Wegener\u2019s granulomatosis: Incidence and relation to cyclophosphamide therapy in a cohort of 293 patients.","volume":"35","author":"Faurschou","year":"2008","journal-title":"J Rheumatol"},{"key":"R23-18-20230410","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1093\/ndt\/gfq017","article-title":"Alkylating agents in membranous nephropathy: Efficacy proven beyond doubt.","volume":"25","author":"Hofstra","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"R24-18-20230410","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/ndt\/gfr220","article-title":"Idiopathic membranous nephropathy and nephrotic syndrome: Outcome in the era of evidence-based therapy.","volume":"27","author":"McQuarrie","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"R25-18-20230410","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1053\/j.ajkd.2007.06.003","article-title":"Long-term risk of cancer in membranous nephropathy patients.","volume":"50","author":"Bj\u00f8rneklett","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"R26-18-20230410","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/ki.1997.127","article-title":"Validation of a predictive model of idiopathic membranous nephropathy: Its clinical and research implications.","volume":"51","author":"Cattran","year":"1997","journal-title":"Kidney Int"},{"key":"R27-18-20230410","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1681\/ASN.2004040287","article-title":"Urinary excretion of beta2-microglobulin and IgG predict prognosis in idiopathic membranous nephropathy: A validation study.","volume":"16","author":"Branten","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R28-18-20230410","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1053\/j.ajkd.2007.05.015","article-title":"Mycophenolate mofetil in idiopathic membranous nephropathy: A clinical trial with comparison to a historic control group treated with cyclophosphamide.","volume":"50","author":"Branten","year":"2007","journal-title":"Am J Kidney Dis"}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00001751-201401000-00018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:23:09Z","timestamp":1786130589000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001751-201401000-00018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.2013020185","relation":{},"ISSN":["1046-6673"],"issn-type":[{"value":"1046-6673","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]}}}